Immunosuppression in liver transplantation

Liver Transplantation

Volumn 11, Issue 11, 2005, Pages 1307-1314

  Post, David J ^a   Douglas, David D ^a   Mulligan, David C ^a  

^a MAYO CLINIC HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIFUNGAL AGENT; ANTIMETABOLITE; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHILIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; MACROLIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PROBENECID; PROKINETIC AGENT; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ANEMIA; ARTERY THROMBOSIS; ARTICLE; BACTERIAL INFECTION; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; BRONCHOSPASM; CATARACT; CELLULAR IMMUNITY; CHILL; CLINICAL TRIAL; CUSHINGOID SYNDROME; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DOSE CALCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DYSLIPIDEMIA; DYSPNEA; FLU LIKE SYNDROME; FLUID RETENTION; GASTRITIS; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GRAFT SURVIVAL; HALLUCINATION; HEADACHE; HELPER CELL; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG EDEMA; LYMPHOCELE; MOUTH ULCER; MUSCLE WEAKNESS; MYCOSIS; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OSTEOPOROSIS; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; SEIZURE; SIDE EFFECT; STOMACH ULCER; SURVIVAL RATE; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TREMOR; VOMITING; WEIGHT REDUCTION; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; PROGNOSIS; SURVIVAL RATE; TRANSPLANTATION IMMUNOLOGY;

EID: 30444443455     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20614     Document Type: Article

References (36)

1. Calne SRY. The future of organ transplantation - From the Laboratory to the Clinic. In: World Congress on Medicine and Health; 2000; Hannover Conference Center; Hannover, Germany: July 21-August 31, 2000.
2. Harrison JH, Merrill JP, Murray JE. Renal homotransplantation in identical twins. Surg Forum 1956;6:432-436.
3. Starzl TE, Koep LJ, Halgrimson CG, Hood J, Schroter GP, Porter KA, Weil R, 3rd. Fifteen years of clinical liver transplantation. Gastroenterology 1979;77:375-388.
4. Van Thiel DH, Makowka L, Starzl TE. Liver transplantation: Where it's been and where it's going. Gastroenterol Clin North Am 1988;17:1-18.
5. Starzl TE, Iwatsuki S, Van Thiel DH, Gartner JC, Zitelli BJ, Malatack JJ, et al. Evolution of liver transplantation. Hepatology 1982;2:614-636.
6. Calne RY, Williams R. Orthotopic liver transplantation: The first 60 patients. Br Med J 1977;1:471-476.
7. Novartis. History of Sandimmune. Available at http://www.novartis-transplant.com/history/history_sandimmune.jsp. Accessed September 23, 2005.
8. Noble S, Markham A. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs 1995;50:924-941.
9. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001;72:1934-1939.
10. Schrem H, Luck R, Becker T, Nashan B, Klempnauer J. Update on liver transplantation using cyclosporine. Transplant Proc 2004;36:2525-2531.
11. Otto MG, Mayer AD, Clavien PA, Cavallari A, Gunawardena KA, Mueller EA. Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral. Transplantation 1998;66:1632-1640.
12. Hemming AW, Greig PD, Cattral MS, Chung SW, Lilly LB, Aljumah AA, Levy GA. A microemulsion of cyclosporine without intravenous cyclosporine in liver transplantation. Transplantation 1996;62:1798-1802.
13. Villamil F, Pollard S. C2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician;s perspective. Liver Transpl 2004;10:577-583.
14. Duffield J. History of FK506 Devolpment. In: Rossi L, ed. Pittsburgh, PA: University of Pittsburgh Medical Center, 1991:1-4.
15. Komolmit P, Davies MH. Tacrolimus in liver transplantation. Expert Opin Investig Drugs 1999;8:1239-1254.
16. Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: A report of the United States FK506 Study Group. Transplantation 1998;66:493-499.
17. OPTN/SRTR. Immunosuppression: Evolution in practice and trends, 1993-2003. In: Miller SN, Finley MP, Li S, eds. Annual Report 2004. Ann Arbor, MI: OPTN/SRTR, 2004.
18. Danovitch G. Immunosuppressive medications and protocols. In: Danovitch GM, ed. Handbook of Kidney Transplantation. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:82-83.
19. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999;21:35-43.
20. Fung J, Kelly D, Kadry Z, Patel-Tom K, Eghtesad B. Immunosuppression in liver transplantation:Beyond calcineurin inhibitors. Liver Transpl 2005;11:267-280.
21. Cosimi AB, Jenkins RL, Rohrer RJ, Delmonico FL, Hoffman M, Monaco AP. A randomized clinical trial of prophylactic OKT3 monoclonal antibody in liver allograft recipients. Arch Surg 1990;125:781-784;discussion 785.
22. Klintmalm GB, Nery JR, Husberg BS, Gonwa TA, Tillery GW. Rejection in liver transplantation. Hepatology 1989;10:978-985.
23. Klein A. Tacrolimus rescue in liver transplant patients with refractory rejection or intolerance or malabsorption of cyclosporine. The US Multicenter FK506 Liver Study Group. Liver Transpl Surg 1999;5:502-508.
24. Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002;8:132-142.
25. Sehgal SN. Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35(Suppl):7S-14S.
26. McAlister VC, Peltekian KM, Malatjalian DA, Colohan S, MacDonald S, Bitter-Suermann H, et al. Orthotopic liver transplantation using low dose tacrolimus and sirolimus. Liver Transpl 2001;7:701-708.
27. McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000;355:376-377.
28. Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: Results of a prospective randomized trial. Liver Transpl 2001;7:693-697.
29. Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: A large randomized clinical study. Liver Transpl 2005;11:61-67.
30. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-940.
31. Reich DJ, Clavien PA, Hodge EE. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: Randomized, prospective, multicenter pilot study results. Transplantation 2005;80:18-25.
32. Schlitt HJ, Barkmann A, Boker KH, Schmidt HH, Emmanouilidis N, Rosenau J, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 2001;357:587-591.
33. Hong M, Angus PW, Jones RM, Vaughan RB, Gow PJ. Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction. Clin Transplant 2005;19:193-198.
34. Lam P, Yoshida A, Brown K, Abouljoud M, Bajjoka I, Dagher F, Moonka DK. The efficacy and limitations of sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors. Dig Dis Sci 2004;49:1029-1035.
35. Shapiro R, Young JB, Milford EL, Trotter JF, Bustami RT, Leichtman AB. Immunosuppression: Evolution in practice and trends, 1993-2003. Am J Transplant 2005;5:874-886.
36. Thomas FT, Lee HM, Lower RR, Thomas JM. Immunological monitoring as a guide to the management of transplant recipients. Surg Clin North Am 1979;59:253-281.